Reponex Pharmaceuticals A/S   Report issue

For profit Phase 2
Founded: Hørsholm Denmark (2006)

Organization Overview

First Clinical Trial
2020
NCT04312360
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Reponex Pharmaceuticals A/S

Active Ingredients

Drugs in Phase 2 Trials (3)

fosfomycin (monurol) (1 trial)

metronidazole (flagyl) (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoma (Phase 2)

Colonic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3